Conformational flexibility of the glycosidase NagZ allows it to bind structurally diverse inhibitors to suppress β-lactam antibiotic resistance.
Identifieur interne : 004572 ( Ncbi/Merge ); précédent : 004571; suivant : 004573Conformational flexibility of the glycosidase NagZ allows it to bind structurally diverse inhibitors to suppress β-lactam antibiotic resistance.
Auteurs : Grishma Vadlamani [Canada] ; Keith A. Stubbs [Australie] ; Jérôme Désiré [France] ; Yves Blériot [France] ; David J. Vocadlo ; Brian L. Mark [Canada]Source :
- Protein science : a publication of the Protein Society [ 1469-896X ] ; 2017.
Descripteurs français
- KwdFr :
- Acétyl-glucosamine (), Acétyl-glucosamine (analogues et dérivés), Domaines protéiques, Escherichia coli (enzymologie), Escherichia coli (génétique), Glycosidases (), Glycosidases (antagonistes et inhibiteurs), Glycosidases (génétique), Oximes (), Phényl-carbamates (), Protéines Escherichia coli (), Protéines Escherichia coli (antagonistes et inhibiteurs), Protéines Escherichia coli (génétique), Résistance aux bêta-lactamines, Structure secondaire des protéines.
- MESH :
- analogues et dérivés : Acétyl-glucosamine.
- antagonistes et inhibiteurs : Glycosidases, Protéines Escherichia coli.
- enzymologie : Escherichia coli.
- génétique : Escherichia coli, Glycosidases, Protéines Escherichia coli.
- Acétyl-glucosamine, Domaines protéiques, Glycosidases, Oximes, Phényl-carbamates, Protéines Escherichia coli, Résistance aux bêta-lactamines, Structure secondaire des protéines.
English descriptors
- KwdEn :
- Acetylglucosamine (analogs & derivatives), Acetylglucosamine (chemistry), Escherichia coli (enzymology), Escherichia coli (genetics), Escherichia coli Proteins (antagonists & inhibitors), Escherichia coli Proteins (chemistry), Escherichia coli Proteins (genetics), Glycoside Hydrolases (antagonists & inhibitors), Glycoside Hydrolases (chemistry), Glycoside Hydrolases (genetics), Oximes (chemistry), Phenylcarbamates (chemistry), Protein Domains, Protein Structure, Secondary, beta-Lactam Resistance.
- MESH :
- chemical , analogs & derivatives : Acetylglucosamine.
- chemical , antagonists & inhibitors : Escherichia coli Proteins, Glycoside Hydrolases.
- chemical , chemistry : Acetylglucosamine, Escherichia coli Proteins, Glycoside Hydrolases, Oximes, Phenylcarbamates.
- enzymology : Escherichia coli.
- genetics : Escherichia coli, Escherichia coli Proteins, Glycoside Hydrolases.
- Protein Domains, Protein Structure, Secondary, beta-Lactam Resistance.
Abstract
NagZ is an N-acetyl-β-d-glucosaminidase that participates in the peptidoglycan (PG) recycling pathway of Gram-negative bacteria by removing N-acetyl-glucosamine (GlcNAc) from PG fragments that have been excised from the cell wall during growth. The 1,6-anhydromuramoyl-peptide products generated by NagZ activate β-lactam resistance in many Gram-negative bacteria by inducing the expression of AmpC β-lactamase. Blocking NagZ activity can thereby suppress β-lactam antibiotic resistance in these bacteria. The NagZ active site is dynamic and it accommodates distortion of the glycan substrate during catalysis using a mobile catalytic loop that carries a histidine residue which serves as the active site general acid/base catalyst. Here, we show that flexibility of this catalytic loop also accommodates structural differences in small molecule inhibitors of NagZ, which could be exploited to improve inhibitor specificity. X-ray structures of NagZ bound to the potent yet non-selective N-acetyl-β-glucosaminidase inhibitor PUGNAc (O-(2-acetamido-2-deoxy-d-glucopyranosylidene) amino-N-phenylcarbamate), and two NagZ-selective inhibitors - EtBuPUG, a PUGNAc derivative bearing a 2-N-ethylbutyryl group, and MM-156, a 3-N-butyryl trihydroxyazepane, revealed that the phenylcarbamate moiety of PUGNAc and EtBuPUG completely displaces the catalytic loop from the NagZ active site to yield a catalytically incompetent form of the enzyme. In contrast, the catalytic loop was found positioned in the catalytically active conformation within the NagZ active site when bound to MM-156, which lacks the phenylcarbamate extension. Displacement of the catalytic loop by PUGNAc and its N-acyl derivative EtBuPUG alters the active site conformation of NagZ, which presents an additional strategy to improve the potency and specificity of NagZ inhibitors.
DOI: 10.1002/pro.3166
PubMed: 28370529
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000A59
- to stream PubMed, to step Curation: 000A56
- to stream PubMed, to step Checkpoint: 000A56
Links to Exploration step
pubmed:28370529Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Conformational flexibility of the glycosidase NagZ allows it to bind structurally diverse inhibitors to suppress β-lactam antibiotic resistance.</title><author><name sortKey="Vadlamani, Grishma" sort="Vadlamani, Grishma" uniqKey="Vadlamani G" first="Grishma" last="Vadlamani">Grishma Vadlamani</name><affiliation wicri:level="4"><nlm:affiliation>Department of Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada, R3T2N2.</nlm:affiliation><orgName type="university">Université du Manitoba</orgName><country>Canada</country><placeName><settlement type="city">Winnipeg</settlement><region type="state">Manitoba</region></placeName></affiliation></author><author><name sortKey="Stubbs, Keith A" sort="Stubbs, Keith A" uniqKey="Stubbs K" first="Keith A" last="Stubbs">Keith A. Stubbs</name><affiliation wicri:level="1"><nlm:affiliation>School of Molecular Sciences, University of Western Australia, Crawley, Western Australia, 6009, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>School of Molecular Sciences, University of Western Australia, Crawley, Western Australia, 6009</wicri:regionArea><wicri:noRegion>6009</wicri:noRegion></affiliation></author><author><name sortKey="Desire, Jerome" sort="Desire, Jerome" uniqKey="Desire J" first="Jérôme" last="Désiré">Jérôme Désiré</name><affiliation wicri:level="4"><nlm:affiliation>IC2MP, UMR CNRS 7285, Équipe "Synthèse Organique" Groupe Glycochimie, Université de Poitiers, 4 rue Michel Brunet, 86073, Poitiers cedex 9, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>IC2MP, UMR CNRS 7285, Équipe "Synthèse Organique" Groupe Glycochimie, Université de Poitiers, 4 rue Michel Brunet, 86073, Poitiers cedex 9</wicri:regionArea><wicri:noRegion>86073, Poitiers cedex 9</wicri:noRegion><orgName type="university">Université de Poitiers</orgName><placeName><settlement type="city">Poitiers</settlement><region type="region" nuts="2">Poitou-Charentes</region></placeName></affiliation></author><author><name sortKey="Bleriot, Yves" sort="Bleriot, Yves" uniqKey="Bleriot Y" first="Yves" last="Blériot">Yves Blériot</name><affiliation wicri:level="4"><nlm:affiliation>IC2MP, UMR CNRS 7285, Équipe "Synthèse Organique" Groupe Glycochimie, Université de Poitiers, 4 rue Michel Brunet, 86073, Poitiers cedex 9, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>IC2MP, UMR CNRS 7285, Équipe "Synthèse Organique" Groupe Glycochimie, Université de Poitiers, 4 rue Michel Brunet, 86073, Poitiers cedex 9</wicri:regionArea><wicri:noRegion>86073, Poitiers cedex 9</wicri:noRegion><orgName type="university">Université de Poitiers</orgName><placeName><settlement type="city">Poitiers</settlement><region type="region" nuts="2">Poitou-Charentes</region></placeName></affiliation></author><author><name sortKey="Vocadlo, David J" sort="Vocadlo, David J" uniqKey="Vocadlo D" first="David J" last="Vocadlo">David J. Vocadlo</name><affiliation><nlm:affiliation>Department of Chemistry, Simon Fraser University, 8888 University Drive, Burnaby, British Columbia, Canada, V5S 1P6.</nlm:affiliation><wicri:noCountry code="subField">V5S 1P6</wicri:noCountry></affiliation></author><author><name sortKey="Mark, Brian L" sort="Mark, Brian L" uniqKey="Mark B" first="Brian L" last="Mark">Brian L. Mark</name><affiliation wicri:level="4"><nlm:affiliation>Department of Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada, R3T2N2.</nlm:affiliation><orgName type="university">Université du Manitoba</orgName><country>Canada</country><placeName><settlement type="city">Winnipeg</settlement><region type="state">Manitoba</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28370529</idno><idno type="pmid">28370529</idno><idno type="doi">10.1002/pro.3166</idno><idno type="wicri:Area/PubMed/Corpus">000A59</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000A59</idno><idno type="wicri:Area/PubMed/Curation">000A56</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000A56</idno><idno type="wicri:Area/PubMed/Checkpoint">000A56</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000A56</idno><idno type="wicri:Area/Ncbi/Merge">004572</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Conformational flexibility of the glycosidase NagZ allows it to bind structurally diverse inhibitors to suppress β-lactam antibiotic resistance.</title><author><name sortKey="Vadlamani, Grishma" sort="Vadlamani, Grishma" uniqKey="Vadlamani G" first="Grishma" last="Vadlamani">Grishma Vadlamani</name><affiliation wicri:level="4"><nlm:affiliation>Department of Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada, R3T2N2.</nlm:affiliation><orgName type="university">Université du Manitoba</orgName><country>Canada</country><placeName><settlement type="city">Winnipeg</settlement><region type="state">Manitoba</region></placeName></affiliation></author><author><name sortKey="Stubbs, Keith A" sort="Stubbs, Keith A" uniqKey="Stubbs K" first="Keith A" last="Stubbs">Keith A. Stubbs</name><affiliation wicri:level="1"><nlm:affiliation>School of Molecular Sciences, University of Western Australia, Crawley, Western Australia, 6009, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>School of Molecular Sciences, University of Western Australia, Crawley, Western Australia, 6009</wicri:regionArea><wicri:noRegion>6009</wicri:noRegion></affiliation></author><author><name sortKey="Desire, Jerome" sort="Desire, Jerome" uniqKey="Desire J" first="Jérôme" last="Désiré">Jérôme Désiré</name><affiliation wicri:level="4"><nlm:affiliation>IC2MP, UMR CNRS 7285, Équipe "Synthèse Organique" Groupe Glycochimie, Université de Poitiers, 4 rue Michel Brunet, 86073, Poitiers cedex 9, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>IC2MP, UMR CNRS 7285, Équipe "Synthèse Organique" Groupe Glycochimie, Université de Poitiers, 4 rue Michel Brunet, 86073, Poitiers cedex 9</wicri:regionArea><wicri:noRegion>86073, Poitiers cedex 9</wicri:noRegion><orgName type="university">Université de Poitiers</orgName><placeName><settlement type="city">Poitiers</settlement><region type="region" nuts="2">Poitou-Charentes</region></placeName></affiliation></author><author><name sortKey="Bleriot, Yves" sort="Bleriot, Yves" uniqKey="Bleriot Y" first="Yves" last="Blériot">Yves Blériot</name><affiliation wicri:level="4"><nlm:affiliation>IC2MP, UMR CNRS 7285, Équipe "Synthèse Organique" Groupe Glycochimie, Université de Poitiers, 4 rue Michel Brunet, 86073, Poitiers cedex 9, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>IC2MP, UMR CNRS 7285, Équipe "Synthèse Organique" Groupe Glycochimie, Université de Poitiers, 4 rue Michel Brunet, 86073, Poitiers cedex 9</wicri:regionArea><wicri:noRegion>86073, Poitiers cedex 9</wicri:noRegion><orgName type="university">Université de Poitiers</orgName><placeName><settlement type="city">Poitiers</settlement><region type="region" nuts="2">Poitou-Charentes</region></placeName></affiliation></author><author><name sortKey="Vocadlo, David J" sort="Vocadlo, David J" uniqKey="Vocadlo D" first="David J" last="Vocadlo">David J. Vocadlo</name><affiliation><nlm:affiliation>Department of Chemistry, Simon Fraser University, 8888 University Drive, Burnaby, British Columbia, Canada, V5S 1P6.</nlm:affiliation><wicri:noCountry code="subField">V5S 1P6</wicri:noCountry></affiliation></author><author><name sortKey="Mark, Brian L" sort="Mark, Brian L" uniqKey="Mark B" first="Brian L" last="Mark">Brian L. Mark</name><affiliation wicri:level="4"><nlm:affiliation>Department of Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada, R3T2N2.</nlm:affiliation><orgName type="university">Université du Manitoba</orgName><country>Canada</country><placeName><settlement type="city">Winnipeg</settlement><region type="state">Manitoba</region></placeName></affiliation></author></analytic><series><title level="j">Protein science : a publication of the Protein Society</title><idno type="eISSN">1469-896X</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acetylglucosamine (analogs & derivatives)</term><term>Acetylglucosamine (chemistry)</term><term>Escherichia coli (enzymology)</term><term>Escherichia coli (genetics)</term><term>Escherichia coli Proteins (antagonists & inhibitors)</term><term>Escherichia coli Proteins (chemistry)</term><term>Escherichia coli Proteins (genetics)</term><term>Glycoside Hydrolases (antagonists & inhibitors)</term><term>Glycoside Hydrolases (chemistry)</term><term>Glycoside Hydrolases (genetics)</term><term>Oximes (chemistry)</term><term>Phenylcarbamates (chemistry)</term><term>Protein Domains</term><term>Protein Structure, Secondary</term><term>beta-Lactam Resistance</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Acétyl-glucosamine ()</term><term>Acétyl-glucosamine (analogues et dérivés)</term><term>Domaines protéiques</term><term>Escherichia coli (enzymologie)</term><term>Escherichia coli (génétique)</term><term>Glycosidases ()</term><term>Glycosidases (antagonistes et inhibiteurs)</term><term>Glycosidases (génétique)</term><term>Oximes ()</term><term>Phényl-carbamates ()</term><term>Protéines Escherichia coli ()</term><term>Protéines Escherichia coli (antagonistes et inhibiteurs)</term><term>Protéines Escherichia coli (génétique)</term><term>Résistance aux bêta-lactamines</term><term>Structure secondaire des protéines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Acetylglucosamine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Escherichia coli Proteins</term><term>Glycoside Hydrolases</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Acetylglucosamine</term><term>Escherichia coli Proteins</term><term>Glycoside Hydrolases</term><term>Oximes</term><term>Phenylcarbamates</term></keywords><keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>Acétyl-glucosamine</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Glycosidases</term><term>Protéines Escherichia coli</term></keywords><keywords scheme="MESH" qualifier="enzymologie" xml:lang="fr"><term>Escherichia coli</term></keywords><keywords scheme="MESH" qualifier="enzymology" xml:lang="en"><term>Escherichia coli</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Escherichia coli</term><term>Escherichia coli Proteins</term><term>Glycoside Hydrolases</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Escherichia coli</term><term>Glycosidases</term><term>Protéines Escherichia coli</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Protein Domains</term><term>Protein Structure, Secondary</term><term>beta-Lactam Resistance</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Acétyl-glucosamine</term><term>Domaines protéiques</term><term>Glycosidases</term><term>Oximes</term><term>Phényl-carbamates</term><term>Protéines Escherichia coli</term><term>Résistance aux bêta-lactamines</term><term>Structure secondaire des protéines</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">NagZ is an N-acetyl-β-d-glucosaminidase that participates in the peptidoglycan (PG) recycling pathway of Gram-negative bacteria by removing N-acetyl-glucosamine (GlcNAc) from PG fragments that have been excised from the cell wall during growth. The 1,6-anhydromuramoyl-peptide products generated by NagZ activate β-lactam resistance in many Gram-negative bacteria by inducing the expression of AmpC β-lactamase. Blocking NagZ activity can thereby suppress β-lactam antibiotic resistance in these bacteria. The NagZ active site is dynamic and it accommodates distortion of the glycan substrate during catalysis using a mobile catalytic loop that carries a histidine residue which serves as the active site general acid/base catalyst. Here, we show that flexibility of this catalytic loop also accommodates structural differences in small molecule inhibitors of NagZ, which could be exploited to improve inhibitor specificity. X-ray structures of NagZ bound to the potent yet non-selective N-acetyl-β-glucosaminidase inhibitor PUGNAc (O-(2-acetamido-2-deoxy-d-glucopyranosylidene) amino-N-phenylcarbamate), and two NagZ-selective inhibitors - EtBuPUG, a PUGNAc derivative bearing a 2-N-ethylbutyryl group, and MM-156, a 3-N-butyryl trihydroxyazepane, revealed that the phenylcarbamate moiety of PUGNAc and EtBuPUG completely displaces the catalytic loop from the NagZ active site to yield a catalytically incompetent form of the enzyme. In contrast, the catalytic loop was found positioned in the catalytically active conformation within the NagZ active site when bound to MM-156, which lacks the phenylcarbamate extension. Displacement of the catalytic loop by PUGNAc and its N-acyl derivative EtBuPUG alters the active site conformation of NagZ, which presents an additional strategy to improve the potency and specificity of NagZ inhibitors.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28370529</PMID><DateCreated><Year>2017</Year><Month>04</Month><Day>03</Day></DateCreated><DateCompleted><Year>2017</Year><Month>07</Month><Day>17</Day></DateCompleted><DateRevised><Year>2017</Year><Month>07</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1469-896X</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>6</Issue><PubDate><Year>2017</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Protein science : a publication of the Protein Society</Title><ISOAbbreviation>Protein Sci.</ISOAbbreviation></Journal><ArticleTitle>Conformational flexibility of the glycosidase NagZ allows it to bind structurally diverse inhibitors to suppress β-lactam antibiotic resistance.</ArticleTitle><Pagination><MedlinePgn>1161-1170</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/pro.3166</ELocationID><Abstract><AbstractText>NagZ is an N-acetyl-β-d-glucosaminidase that participates in the peptidoglycan (PG) recycling pathway of Gram-negative bacteria by removing N-acetyl-glucosamine (GlcNAc) from PG fragments that have been excised from the cell wall during growth. The 1,6-anhydromuramoyl-peptide products generated by NagZ activate β-lactam resistance in many Gram-negative bacteria by inducing the expression of AmpC β-lactamase. Blocking NagZ activity can thereby suppress β-lactam antibiotic resistance in these bacteria. The NagZ active site is dynamic and it accommodates distortion of the glycan substrate during catalysis using a mobile catalytic loop that carries a histidine residue which serves as the active site general acid/base catalyst. Here, we show that flexibility of this catalytic loop also accommodates structural differences in small molecule inhibitors of NagZ, which could be exploited to improve inhibitor specificity. X-ray structures of NagZ bound to the potent yet non-selective N-acetyl-β-glucosaminidase inhibitor PUGNAc (O-(2-acetamido-2-deoxy-d-glucopyranosylidene) amino-N-phenylcarbamate), and two NagZ-selective inhibitors - EtBuPUG, a PUGNAc derivative bearing a 2-N-ethylbutyryl group, and MM-156, a 3-N-butyryl trihydroxyazepane, revealed that the phenylcarbamate moiety of PUGNAc and EtBuPUG completely displaces the catalytic loop from the NagZ active site to yield a catalytically incompetent form of the enzyme. In contrast, the catalytic loop was found positioned in the catalytically active conformation within the NagZ active site when bound to MM-156, which lacks the phenylcarbamate extension. Displacement of the catalytic loop by PUGNAc and its N-acyl derivative EtBuPUG alters the active site conformation of NagZ, which presents an additional strategy to improve the potency and specificity of NagZ inhibitors.</AbstractText><CopyrightInformation>© 2017 The Protein Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vadlamani</LastName><ForeName>Grishma</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada, R3T2N2.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stubbs</LastName><ForeName>Keith A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>School of Molecular Sciences, University of Western Australia, Crawley, Western Australia, 6009, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Désiré</LastName><ForeName>Jérôme</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>IC2MP, UMR CNRS 7285, Équipe "Synthèse Organique" Groupe Glycochimie, Université de Poitiers, 4 rue Michel Brunet, 86073, Poitiers cedex 9, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blériot</LastName><ForeName>Yves</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>IC2MP, UMR CNRS 7285, Équipe "Synthèse Organique" Groupe Glycochimie, Université de Poitiers, 4 rue Michel Brunet, 86073, Poitiers cedex 9, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vocadlo</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Simon Fraser University, 8888 University Drive, Burnaby, British Columbia, Canada, V5S 1P6.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mark</LastName><ForeName>Brian L</ForeName><Initials>BL</Initials><AffiliationInfo><Affiliation>Department of Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada, R3T2N2.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>04</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Protein Sci</MedlineTA><NlmUniqueID>9211750</NlmUniqueID><ISSNLinking>0961-8368</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D029968">Escherichia coli Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010091">Oximes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D048448">Phenylcarbamates</NameOfSubstance></Chemical><Chemical><RegistryNumber>132489-69-1</RegistryNumber><NameOfSubstance UI="C068836">N-acetylglucosaminono-1,5-lactone O-(phenylcarbamoyl)oxime</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.2.1.-</RegistryNumber><NameOfSubstance UI="D006026">Glycoside Hydrolases</NameOfSubstance></Chemical><Chemical><RegistryNumber>V956696549</RegistryNumber><NameOfSubstance UI="D000117">Acetylglucosamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Acta Crystallogr D Biol Crystallogr. 2011 Apr;67(Pt 4):271-81</RefSource><PMID Version="1">21460445</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Antimicrob Agents Chemother. 1997 Oct;41(10):2113-20</RefSource><PMID Version="1">9333034</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Acta Crystallogr D Biol Crystallogr. 2006 Jan;62(Pt 1):72-82</RefSource><PMID Version="1">16369096</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Bioorg Med Chem. 2009 Aug 1;17(15):5598-604</RefSource><PMID Version="1">19592259</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Chem Commun (Camb). 2013 Dec 4;49(93):10983-5</RefSource><PMID Version="1">24136176</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Antimicrob Agents Chemother. 2009 Jun;53(6):2274-82</RefSource><PMID Version="1">19273679</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Protein Sci. 2009 Jul;18(7):1541-51</RefSource><PMID Version="1">19499593</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Antimicrob Agents Chemother. 2010 Sep;54(9):3557-63</RefSource><PMID Version="1">20566764</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Acc Chem Res. 2000 Jan;33(1):11-8</RefSource><PMID Version="1">10639071</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Biol Chem. 2000 Dec 15;275(50):39032-8</RefSource><PMID Version="1">10978324</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Biol Chem. 2015 Feb 20;290(8):4887-95</RefSource><PMID Version="1">25533455</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biochem J. 1996 Jun 1;316 ( Pt 2):695-6</RefSource><PMID Version="1">8687420</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>EMBO J. 1994 Oct 3;13(19):4684-94</RefSource><PMID Version="1">7925310</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Org Biomol Chem. 2006 Mar 7;4(5):839-45</RefSource><PMID Version="1">16493467</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Appl Microbiol Biotechnol. 2011 Oct;92(1):1-11</RefSource><PMID Version="1">21796380</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Curr Opin Chem Biol. 2008 Oct;12(5):539-55</RefSource><PMID Version="1">18558099</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nucleic Acids Res. 2014 Jan;42(Database issue):D490-5</RefSource><PMID Version="1">24270786</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Struct Biol. 1996 Jul;3(7):638-48</RefSource><PMID Version="1">8673609</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Biol Chem. 2007 Jul 20;282(29):21382-91</RefSource><PMID Version="1">17439950</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Bacteriol. 2000 Sep;182(17):4836-40</RefSource><PMID Version="1">10940025</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biochemistry. 2005 Sep 27;44(38):12809-18</RefSource><PMID Version="1">16171396</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):213-21</RefSource><PMID Version="1">20124702</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Biol Chem. 2010 Nov 12;285(46):35675-84</RefSource><PMID Version="1">20826810</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>ACS Med Chem Lett. 2012 Mar 8;3(3):238-242</RefSource><PMID Version="1">22844551</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Carbohydr Res. 2016 Nov 29;435:106-112</RefSource><PMID Version="1">27744113</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biochemistry. 2000 Jan 11;39(1):117-26</RefSource><PMID Version="1">10625486</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Biochem. 1991 May 8;197(3):815-8</RefSource><PMID Version="1">2029909</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Biol Chem. 2001 Mar 30;276(13):10330-7</RefSource><PMID Version="1">11124970</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Org Biomol Chem. 2016 Apr 7;14 (13):3432-42</RefSource><PMID Version="1">26963691</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cell. 1997 Mar 21;88(6):823-32</RefSource><PMID Version="1">9118225</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Chem Biol. 2012 Nov 21;19(11):1471-82</RefSource><PMID Version="1">23177201</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Acta Crystallogr D Biol Crystallogr. 2004 Dec;60(Pt 12 Pt 1):2126-32</RefSource><PMID Version="1">15572765</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Chembiochem. 2013 Oct 11;14(15):1973-81</RefSource><PMID Version="1">24009110</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000117" MajorTopicYN="N">Acetylglucosamine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs & derivatives</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004926" MajorTopicYN="N">Escherichia coli</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029968" MajorTopicYN="N">Escherichia coli Proteins</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006026" MajorTopicYN="N">Glycoside Hydrolases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010091" MajorTopicYN="N">Oximes</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D048448" MajorTopicYN="N">Phenylcarbamates</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072417" MajorTopicYN="N">Protein Domains</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017433" MajorTopicYN="N">Protein Structure, Secondary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018440" MajorTopicYN="Y">beta-Lactam Resistance</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">AmpC</Keyword><Keyword MajorTopicYN="N">EtBuPUG</Keyword><Keyword MajorTopicYN="N">GH3</Keyword><Keyword MajorTopicYN="N">N-acetyl-β-d-glucosaminidase</Keyword><Keyword MajorTopicYN="N">NagZ</Keyword><Keyword MajorTopicYN="N">PUGNAc</Keyword><Keyword MajorTopicYN="N">family 3</Keyword><Keyword MajorTopicYN="N">trihydroxyazepane</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>03</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>03</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>03</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>06</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>4</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>7</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>4</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28370529</ArticleId><ArticleId IdType="doi">10.1002/pro.3166</ArticleId><ArticleId IdType="pmc">PMC5441427</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Australie</li><li>Canada</li><li>France</li></country><region><li>Manitoba</li><li>Poitou-Charentes</li></region><settlement><li>Poitiers</li><li>Winnipeg</li></settlement><orgName><li>Université de Poitiers</li><li>Université du Manitoba</li></orgName></list><tree><noCountry><name sortKey="Vocadlo, David J" sort="Vocadlo, David J" uniqKey="Vocadlo D" first="David J" last="Vocadlo">David J. Vocadlo</name></noCountry><country name="Canada"><region name="Manitoba"><name sortKey="Vadlamani, Grishma" sort="Vadlamani, Grishma" uniqKey="Vadlamani G" first="Grishma" last="Vadlamani">Grishma Vadlamani</name></region><name sortKey="Mark, Brian L" sort="Mark, Brian L" uniqKey="Mark B" first="Brian L" last="Mark">Brian L. Mark</name></country><country name="Australie"><noRegion><name sortKey="Stubbs, Keith A" sort="Stubbs, Keith A" uniqKey="Stubbs K" first="Keith A" last="Stubbs">Keith A. Stubbs</name></noRegion></country><country name="France"><region name="Poitou-Charentes"><name sortKey="Desire, Jerome" sort="Desire, Jerome" uniqKey="Desire J" first="Jérôme" last="Désiré">Jérôme Désiré</name></region><name sortKey="Bleriot, Yves" sort="Bleriot, Yves" uniqKey="Bleriot Y" first="Yves" last="Blériot">Yves Blériot</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004572 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 004572 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:28370529
|texte= Conformational flexibility of the glycosidase NagZ allows it to bind structurally diverse inhibitors to suppress β-lactam antibiotic resistance.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:28370529" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |